JPRN-jRCT2051230127招募中3 期
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom - DAISY
Ageishi Yuji0 个研究点目标入组 32 人开始时间: 2023年11月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 < 70age old（—）
- 性别
- All
入选标准
- •1. Adult patients from 18 to 70 years of age inclusive
- •2. Systemic sclerosis according to 2013 ACR/EULAR classification criteria
- •3. Limited or diffuse cutaneous subsets
- •4. Systemic sclerosis disease duration within 6 years from first non-Raynaud's phenomenon manifestation
- •5. Either HAQ-DI score 0.25 points or more or PtGA score 3 points or more
- •6. mRSS > 10 with early disease or rapid progression as defined by the protocol
- •7. mRSS 15 or more with disease duration 18 months or more and active disease as defined by the protocol
- •8. Stable background therapies can be used including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, mycophenolic sodium, mycophenolic acid, oral glucocorticoids or tacrolimus
- •9. Women of childbearing potential with a negative urine pregnancy test
- •10. Uninvolved skin at injection sites
排除标准
- •1. Anticentromere antibody seropositivity on central laboratory
- •2. Severe cardiopulmonary disease as defined by the protocol
- •3. History of systemic sclerosis renal crisis within past 12 months (estimated glomerular filtration rate(eGFR) < 45 mL/min)
- •4. Overlap syndromes, systemic lupus erythematosus with anti-double-stranded deoxyribonucleic acid antibody seropositivity or anti-citrullinated protein antibodies-positive rheumatoid arthritis, or SSc mimics (eg, scleromyxedema, eosinophilic fasciitis)
- •5. History of, or current, any other inflammatory diseases, eg, inflammatory bowel disease, skin disease, that, in the opinion of the investigator, could interfere with efficacy and safety assessments or require immunomodulatory therapy
- •6. Evidence of moderately severe concurrent nervous system, renal, endocrine, hepatic (eg, underlying chronic liver disease [Child Pugh A, B, C hepatic impairment]), or gastrointestinal disease (eg, clinical signs of malabsorption or needing parenteral nutrition) not related to SSc, as determined by the investigator
- •7. Hematopoietic stem cell transplantation or solid organ/limb transplantation
- •8. Any severe case of Herpes Zoster infection as defined by the protocol
- •9. Known malignancy or a history of malignancy within 5 years, with exception of excised/cured local basal or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix
- •10. Major surgery within 8 weeks prior to and/or during study enrollment
- •11. Known active current or history of recurrent infections
- •12. Severe cardiopulmonary disease
- •13. Any condition that, in the opinion of the investigator or AstraZeneca, would interfere with the efficacy or safety evaluation of the study intervention or put participant at safety risk
研究者
相似试验
招募中
3 期
A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisJPRN-jRCT2011210060Ageishi Yuji360
已完成
Unknown
Effectiveness of 0.2% hyaluronic acid on clinical, biomolecular and microbiological parameters in type 2 diabetes mellitus patients with periodontitis: a randomized clinical trialISRCTN49272905niversity of Indonesia36
已完成
不适用
The effect of Manual Lymphatic Drainage to treat leg edema at late pregnancywomen with edema of legs in the third quarter of pregnancyReproductive Health and Childbirth - Normal pregnancyACTRN12611000272998Fapesp20
尚未招募
不适用
Efficacy of a single intravenous venous dose of parecoxib 40 mg for post-operative pain control after elective cesarean delivery: a double blind randomized controlled trialPostpartum womenElective cesarean deliveryParecoxibcesarean deliveryTCTR20140909001Faculty of Medicine. Siriraj Hospital. Mahidol University82
已完成
不适用
Research for objective evaluation of efficacy of anti-Parkinson's drug with repetitive transcranial magneticstimulation in Parkinson's diseaseParkinson's disease.JPRN-UMIN000014287niversity of Tokyo Hospital30